American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
Boston, MA
Presentation Details:
Title: CAR T therapy without preconditioning in pemphigus vulgaris: Early clinical and translational data with resecabtagene autoleucel, an autologous 4-1BB CD19-CAR T
Presentation ID: 3368
Session: Poster Reception
Date and Time: Thursday, May 14, 2026, 5:00 p.m. – 6:30 p.m. ET
Presenter: Jenell Volkov, Ph.D., Senior Director, Translational Medicine, Cabaletta Bio
Title: End-to-end fully automated CAR T manufacturing using the Cellares Cell Shuttle Platform: Initial translational data from autoimmune patients treated in RESET trials with rese-cel (Resecabtagene Autoleucel), an autologous 4-1BB CD19-CAR T cell therapy
Presentation ID: 3379
Session: Poster Reception
Date and Time: Thursday, May 14, 2026, 5:00 p.m. – 6:30 p.m. ET
Presenter: Daniel Nunez, Ph.D., Senior Director, Computational Biology, Cabaletta Bio
Title: Product quality for Resecabtagene autoleucel between healthy donors and autoimmune patients in the RESET clinical trial program starting material is consistent and platform agnostic demonstrating manufacturing robustness in the session Enabling the next generation of manufacturing ex-vivo cell therapies
Session: Enabling the next generation of manufacturing ex-vivo cell therapies
Date and Time: Tuesday, May 12, 2026, 11:00 a.m. ET
Presenter: Sagar Sharma, Scientist, Cabaletta Bio
Title: Single-cell profiling of PBMC subsets following rese-cel (Resecabtagene Autoleucel) treatment across the RESET-Myositis, RESET-SSc, and RESET-SLE trials Phase 1/2 Cohorts
Session: Emerging clinical evidence in cell and gene therapy: Long-term outcomes, biomarkers, and first-in-human insights
Date and Time: Wednesday, May 13, 2026, 8:45 a.m. ET
Presenter: Daniel Nunez, Ph.D., Senior Director, Computational Biology, Cabaletta Bio
Additional information, including the accepted abstracts, can be accessed on the website of the ASGCT 2026 Annual Meeting.